AdjuCor receives further funding for its innovative heart assist device which avoids blood-contact and supports patients with heart failure.
MUNICH, Germany – August 26th, 2019: After reaching a key milestone towards clinical application with a successful 60 day in-vivo study, AdjuCor announces the closure of a new financing round with Hirschvogel Vermögensverwaltung GmbH, a Bavarian Investor who intends to further expand its activity into the medical device arena.
Hirschvogel Vermögensverwaltung GmbH announces its new investment into the innovative MedTech Company AdjuCor to further develop their unique non-blood contacting heart assist device.“This is one of the most outstanding technologies I have seen in the last years”, commented Dr. Marc Hirschvogel, CEO of Hirschvogel Vermögensverwaltung GmbH, and continued:“Having expertise in this field, due to my background in computational mechanics and engineering in cardiovascular medicine, I am convinced that this non-blood-contacting device will set a key milestone in treatment of advanced heart failure and gives engineers room for more exciting products in the future. For us, this investment will be a strategic step towards further activities in the medical device arena.”
Prof. Stephan Schueler, Director of Cardiac Transplant and Assist Device Therapy at Freeman Hospital in Newcastle upon Tyne, UK pointed out that many obstacles in current assist device therapy are directly linked to foreign surfaces contacting the blood stream. “If we would be able to enhance blood pressure and circulation without having to place devices into the heart and major vessels, we could definitively improve the care and the quality of life of our patients. Because the AdjuCor device avoids the blood contact, it has the potential to significantly change the way heart failure patients will be treated. I am looking forward to participate in the clinical study, in the near future.”
AdjuCor’s Innovative Extravascular, Biventricular Cardiac Support Technology
What sets AdjuCor’ patented technology apart from the other LVADs currently available on the market, is its unique non-blood-contacting solution, its ability to support both ventricles, and its innovative patient-specific design. It is implanted by a heart team (cardiologist and cardiac surgeon) around the heart within a few minutes on the beating heart without sutures. It completely avoids blood contact and thereby any blood-related complications including strokes and bleeding – an invaluable advantage that cannot be over-stated. The energy transferred to the heart may be adjusted to each patient’s need. It thereby dramatically enhances the care of patients with heart failure and improves their quality of life.
AdjuCor was founded as GmbH in 2012 by the Cardiothoracic Surgeon Stephen Wildhirt and is funded by private investors, the European Union, as well as German and Bavarian entities. The company employs over thirty experts in all fields required and has received over 13 million euros of financing.
Related products
AdjuCor - Heart Failure Treating Technology
Related news
-
Professional Old Age Home Care Services in Australia
JK Home Care is delighted to extend its range of professional home care services in Australia. Transforming home care solutions, the specialized team of qualified experts at JK Home Care offer world-class therapeutic supports, specialized supported employment, specialized positive behavior support, participation in the community, innovative community participation, home modifications and more aligned to the patient’s requirement. JK Home Care was born out of a desire to care and give back to the community....
-
Lonza and Sheba Medical Center Use Cocoon® Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy
Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon® automated manufacturing Platform The data underscores the capability of Cocoon® to successfully manufacture immunotherapies at the point-of-care Three patients had complete responses, with another patient still under evaluation Tel Aviv, Israel and Basel, Switzerland, 12 August 2021 – Sheba Medical Center at Tel Hashomer, the largest hospital in the...
-
Femasys Inc. Announces First Patient Treated in Pivotal Trial for FemaSeed
First in Class Insemination Treatment for Infertility LOCAL Pivotal Trial to Enroll Up to 792 Patients Across 20 U.S. Centers Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on transforming women`s healthcare, today announced the initiation and first patient treated in a pivotal trial evaluating FemaSeed, a first in class, localized directional insemination product candidate for infertility. “For more than 20 years, current approaches to infertility treatment have been limited during the...
-
Enterome announces first patient dosed in a Phase 1/2 trial with second OncoMimicsTM vaccine, EO2463, in non-Hodgkin lymphoma
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine • EO2463 combines four microbiome-peptides of B lymphocytes-specific lineage markers designed to induce the full depletion of malignant B lymphocytes ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, announces that the first patient was dosed in a Phase 1/2 clinical trial (‘SIDNEY’)...
-
Med Tech Outlook: Top Medical Ventilator Solution Providers 2021
Accurate breath analysis is key for diagnosis and assessment of pulmonary illnesses. Breath analysis is an important evaluation tool to support respiratory therapists and pulmonologists in the diagnosis and treatment of varying respiratory illnesses. Unfortunately, moisture is an impediment to successful breath analysis. Moisture in breath samples can adversely impact the accuracy of breath analysis and damage devices. As such, respiratory device providers seek robust solutions that reduce moisture from breath...
Customer comments
No comments were found for AdjuCor receives further funding for its innovative heart assist device which avoids blood-contact and supports patients with heart failure.. Be the first to comment!